Genetics and Genomics of Hypertrophic Cardiomyopathy

J. Martijn Bos, Steve R. Ommen, Michael John Ackerman

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Hypertrophic cardiomyopathy (HCM) is an unexplained left ventricular hypertrophy (LVH) in the absence of precipitating factors such as hypertension or aortic stenosis. HCM is a disease of enormous phenotypic and genotypic heterogeneity. Affecting 1 in 500 people, it is the most prevalent genetic cardiovascular disease. It can manifest itself with negligible to extreme hypertrophy, minimal to extensive fibrosis and myocyte disarray, absent to severe left ventricular outflow tract obstruction, and distinct patterns of hypertrophy. The clinical presentation of HCM is underscored by extreme variability from an asymptomatic course to that of severe heart failure and arrhythmias. It commonly manifests itself between the second and the fourth decades of life, but can present itself at the extremes of age. Infants and young children may be affected with severe hypertrophy leading to heart failure, and these patients have poor prognosis. The most common symptoms are exertional dyspnea, chest pain, and syncope or presyncope. Approximately 5% of patients with HCM progress to "end-stage" disease characterized by left ventricular dilatation and heart failure. In such cases, cardiac transplantation may be considered. Other serious life-threatening complications include embolic stroke and cardiac arrhythmias. Genetic and clinical screening of family members with HCM plays an important role in its early diagnosis. © 2010

Original languageEnglish (US)
Title of host publicationEssentials of Genomic and Personalized Medicine
PublisherElsevier Inc.
Pages336-349
Number of pages14
ISBN (Print)9780123749345
DOIs
StatePublished - 2010

Fingerprint

Hypertrophic Cardiomyopathy
Genomics
Hypertrophy
Heart Failure
Syncope
Cardiac Arrhythmias
Screening
Ventricular Outflow Obstruction
Precipitating Factors
Inborn Genetic Diseases
Aortic Valve Stenosis
Genetic Testing
Left Ventricular Hypertrophy
Heart Transplantation
Chest Pain
Dyspnea
Muscle Cells
Early Diagnosis
Dilatation
Fibrosis

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Martijn Bos, J., Ommen, S. R., & Ackerman, M. J. (2010). Genetics and Genomics of Hypertrophic Cardiomyopathy. In Essentials of Genomic and Personalized Medicine (pp. 336-349). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-374934-5.00028-3

Genetics and Genomics of Hypertrophic Cardiomyopathy. / Martijn Bos, J.; Ommen, Steve R.; Ackerman, Michael John.

Essentials of Genomic and Personalized Medicine. Elsevier Inc., 2010. p. 336-349.

Research output: Chapter in Book/Report/Conference proceedingChapter

Martijn Bos, J, Ommen, SR & Ackerman, MJ 2010, Genetics and Genomics of Hypertrophic Cardiomyopathy. in Essentials of Genomic and Personalized Medicine. Elsevier Inc., pp. 336-349. https://doi.org/10.1016/B978-0-12-374934-5.00028-3
Martijn Bos J, Ommen SR, Ackerman MJ. Genetics and Genomics of Hypertrophic Cardiomyopathy. In Essentials of Genomic and Personalized Medicine. Elsevier Inc. 2010. p. 336-349 https://doi.org/10.1016/B978-0-12-374934-5.00028-3
Martijn Bos, J. ; Ommen, Steve R. ; Ackerman, Michael John. / Genetics and Genomics of Hypertrophic Cardiomyopathy. Essentials of Genomic and Personalized Medicine. Elsevier Inc., 2010. pp. 336-349
@inbook{909532711bc845298e6ade4953d806fb,
title = "Genetics and Genomics of Hypertrophic Cardiomyopathy",
abstract = "Hypertrophic cardiomyopathy (HCM) is an unexplained left ventricular hypertrophy (LVH) in the absence of precipitating factors such as hypertension or aortic stenosis. HCM is a disease of enormous phenotypic and genotypic heterogeneity. Affecting 1 in 500 people, it is the most prevalent genetic cardiovascular disease. It can manifest itself with negligible to extreme hypertrophy, minimal to extensive fibrosis and myocyte disarray, absent to severe left ventricular outflow tract obstruction, and distinct patterns of hypertrophy. The clinical presentation of HCM is underscored by extreme variability from an asymptomatic course to that of severe heart failure and arrhythmias. It commonly manifests itself between the second and the fourth decades of life, but can present itself at the extremes of age. Infants and young children may be affected with severe hypertrophy leading to heart failure, and these patients have poor prognosis. The most common symptoms are exertional dyspnea, chest pain, and syncope or presyncope. Approximately 5{\%} of patients with HCM progress to {"}end-stage{"} disease characterized by left ventricular dilatation and heart failure. In such cases, cardiac transplantation may be considered. Other serious life-threatening complications include embolic stroke and cardiac arrhythmias. Genetic and clinical screening of family members with HCM plays an important role in its early diagnosis. {\circledC} 2010",
author = "{Martijn Bos}, J. and Ommen, {Steve R.} and Ackerman, {Michael John}",
year = "2010",
doi = "10.1016/B978-0-12-374934-5.00028-3",
language = "English (US)",
isbn = "9780123749345",
pages = "336--349",
booktitle = "Essentials of Genomic and Personalized Medicine",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Genetics and Genomics of Hypertrophic Cardiomyopathy

AU - Martijn Bos, J.

AU - Ommen, Steve R.

AU - Ackerman, Michael John

PY - 2010

Y1 - 2010

N2 - Hypertrophic cardiomyopathy (HCM) is an unexplained left ventricular hypertrophy (LVH) in the absence of precipitating factors such as hypertension or aortic stenosis. HCM is a disease of enormous phenotypic and genotypic heterogeneity. Affecting 1 in 500 people, it is the most prevalent genetic cardiovascular disease. It can manifest itself with negligible to extreme hypertrophy, minimal to extensive fibrosis and myocyte disarray, absent to severe left ventricular outflow tract obstruction, and distinct patterns of hypertrophy. The clinical presentation of HCM is underscored by extreme variability from an asymptomatic course to that of severe heart failure and arrhythmias. It commonly manifests itself between the second and the fourth decades of life, but can present itself at the extremes of age. Infants and young children may be affected with severe hypertrophy leading to heart failure, and these patients have poor prognosis. The most common symptoms are exertional dyspnea, chest pain, and syncope or presyncope. Approximately 5% of patients with HCM progress to "end-stage" disease characterized by left ventricular dilatation and heart failure. In such cases, cardiac transplantation may be considered. Other serious life-threatening complications include embolic stroke and cardiac arrhythmias. Genetic and clinical screening of family members with HCM plays an important role in its early diagnosis. © 2010

AB - Hypertrophic cardiomyopathy (HCM) is an unexplained left ventricular hypertrophy (LVH) in the absence of precipitating factors such as hypertension or aortic stenosis. HCM is a disease of enormous phenotypic and genotypic heterogeneity. Affecting 1 in 500 people, it is the most prevalent genetic cardiovascular disease. It can manifest itself with negligible to extreme hypertrophy, minimal to extensive fibrosis and myocyte disarray, absent to severe left ventricular outflow tract obstruction, and distinct patterns of hypertrophy. The clinical presentation of HCM is underscored by extreme variability from an asymptomatic course to that of severe heart failure and arrhythmias. It commonly manifests itself between the second and the fourth decades of life, but can present itself at the extremes of age. Infants and young children may be affected with severe hypertrophy leading to heart failure, and these patients have poor prognosis. The most common symptoms are exertional dyspnea, chest pain, and syncope or presyncope. Approximately 5% of patients with HCM progress to "end-stage" disease characterized by left ventricular dilatation and heart failure. In such cases, cardiac transplantation may be considered. Other serious life-threatening complications include embolic stroke and cardiac arrhythmias. Genetic and clinical screening of family members with HCM plays an important role in its early diagnosis. © 2010

UR - http://www.scopus.com/inward/record.url?scp=84882770537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882770537&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-374934-5.00028-3

DO - 10.1016/B978-0-12-374934-5.00028-3

M3 - Chapter

AN - SCOPUS:84882770537

SN - 9780123749345

SP - 336

EP - 349

BT - Essentials of Genomic and Personalized Medicine

PB - Elsevier Inc.

ER -